当前位置: 首页 >> 检索结果
2441. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.
作者: Mias Pretorius.;David Rosenbaum.;Douglas E Vaughan.;Nancy J Brown.
来源: Circulation. 2003年107卷4期579-85页
Angiotensin-converting enzyme (ACE) inhibition potentiates the tissue-type plasminogen activator (t-PA) response to exogenous bradykinin. This study tested the hypothesis that ACE inhibition increases endothelial t-PA release through endogenous bradykinin.
2442. Effects of AGI-1067 and probucol after percutaneous coronary interventions.
作者: Jean-Claude Tardif.;Jean Grégoire.;Leonard Schwartz.;Lawrence Title.;Louise Laramée.;François Reeves.;Jacques Lespérance.;Martial G Bourassa.;Philippe L L'Allier.;Mitchell Glass.;Jean Lambert.;Marie-Claude Guertin.; .
来源: Circulation. 2003年107卷4期552-8页
AGI-1067, a metabolically stable modification of probucol, is an equipotent antioxidant to probucol but is pharmacologically distinct. In a multicenter trial, we studied whether AGI-1067 reduces restenosis assessed by intravascular ultrasound (IVUS) after percutaneous coronary intervention (PCI) compared with placebo and probucol used as a positive control.
2443. Intravascular ultrasound-guided balloon angioplasty compared with stent: immediate and 6-month results of the multicenter, randomized Balloon Equivalent to Stent Study (BEST).
作者: François Schiele.;Nicolas Meneveau.;Martine Gilard.;Jacques Boschat.;Philippe Commeau.;Liu Pin Ming.;Pradip Sewoke.;Marie-France Seronde.;Mariette Mercier.;Sanjiv Gupta.;Jean-Pierre Bassand.; .
来源: Circulation. 2003年107卷4期545-51页
Balloon angioplasty guided by intravascular ultrasound (IVUS) makes it possible to choose the balloon size according to the true vessel diameter and to detect suboptimal results requiring subsequent stent implantation. The Balloon Equivalent to STent (BEST) study aimed to assess whether this strategy would give the same results as systematic stenting.
2444. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes.
作者: Christopher Heeschen.;Stefanie Dimmeler.;Christian W Hamm.;Eric Boersma.;Andreas M Zeiher.;Maarten L Simoons.; .
来源: Circulation. 2003年107卷4期524-30页
In patients with acute coronary syndromes, compensatory processes are initiated, including angiogenesis and endothelial regeneration of ruptured or eroded plaques. Angiogenic growth factors like vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) are upregulated during ischemia. However, it is unknown whether their serum levels are related to clinical outcome.
2445. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).
作者: Myeong-Ki Hong.;Gary S Mintz.;Cheol Whan Lee.;Jong-Min Song.;Ki-Hoon Han.;Duk-Hyun Kang.;Jae-Kwan Song.;Jae-Joong Kim.;Neil J Weissman.;Neal E Fearnot.;Seong-Wook Park.;Seung-Jung Park.; .
来源: Circulation. 2003年107卷4期517-20页
The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effect of a paclitaxel coating on in-stent intimal hyperplasia (IH).
2446. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
作者: J P Ottervanger.;P Armstrong.;E S Barnathan.;E Boersma.;J S Cooper.;E M Ohman.;S James.;E Topol.;L Wallentin.;M L Simoons.; .
来源: Circulation. 2003年107卷3期437-42页
This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
2447. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels.
作者: PierMarco Piatti.;Gabriele Fragasso.;Lucilla D Monti.;Emanuela Setola.;Pietro Lucotti.;Isabella Fermo.;Rita Paroni.;Elena Galluccio.;Guido Pozza.;Sergio Chierchia.;Alberto Margonato.
来源: Circulation. 2003年107卷3期429-36页
We tested the hypothesis that asymmetric dimethylarginine (ADMA) levels could be elevated and influence endothelin-1 and nitric oxide release and action in patients with cardiac syndrome X (CSX). In addition, we evaluated whether an intravenous infusion of L-arginine would improve endothelial function in these subjects.
2448. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).
Endothelial dysfunction is an important feature of atherosclerosis. Inhibition of the HMG-CoA pathway and of calcium channels improves endothelial function experimentally and in the forearm circulation. Thus, we investigated the effects of a statin and/or a calcium antagonist on coronary endothelial function in patients with coronary artery disease (CAD).
2449. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers.
作者: Sashi Guthikonda.;Christine Sinkey.;Therese Barenz.;William G Haynes.
来源: Circulation. 2003年107卷3期416-21页
Cigarette smoking causes endothelial dysfunction, possibly through increased oxidant stress. The enzyme xanthine oxidase produces oxidative free radicals. We tested the hypothesis that xanthine oxidase contributes to endothelial dysfunction in cigarette smokers by administering the inhibitor allopurinol.
2450. Selective COX-2 inhibition improves endothelial function in coronary artery disease.
作者: Rémy Chenevard.;David Hürlimann.;Markus Béchir.;Frank Enseleit.;Lukas Spieker.;Matthias Hermann.;Walter Riesen.;Steffen Gay.;Renate E Gay.;Michel Neidhart.;Beat Michel.;Thomas F Lüscher.;Georg Noll.;Frank Ruschitzka.
来源: Circulation. 2003年107卷3期405-9页
There is an ongoing debate as to whether the gastrointestinal safety of COX-2 inhibition compared with nonsteroidal antiinflammatory drugs (NSAIDs) may come at the cost of increased cardiovascular events. In view of the large number of patients at cardiovascular risk requiring chronic analgesic therapy with COX-2 inhibitors for arthritic and other inflammatory conditions, the effects of selective COX-2 inhibition on clinically useful surrogates for cardiovascular disease, particularly endothelial function, need to be determined.
2451. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.
作者: Donna M Mancini.;Stuart D Katz.;Chim C Lang.;John LaManca.;Alhakam Hudaihed.;Ana-Silvia Androne.
来源: Circulation. 2003年107卷2期294-9页
Patients with chronic heart failure (CHF) are frequently anemic. An increase in hemoglobin could enhance exercise performance by increasing oxygen delivery. We investigated the effect of erythropoietin (EPO) on exercise performance in anemic patients with CHF.
2452. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.
作者: Michael H Picard.;Ravin Davidoff.;Lynn A Sleeper.;Lisa A Mendes.;Christopher R Thompson.;Vladimir Dzavik.;Richard Steingart.;Ken Gin.;Harvey D White.;Judith S Hochman.; .
来源: Circulation. 2003年107卷2期279-84页
Although echocardiography is used in diagnosis and management of myocardial infarction, it has not been established whether specific features of cardiac structure or function early in the course of cardiogenic shock provide prognostic value. The purposes of this substudy of the SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK (SHOCK) trial were to describe the echocardiographic features of cardiogenic shock, identify findings on early echocardiograms associated with outcome, examine the interaction of such features with treatment, and determine whether these features could provide insights into the survival benefit observed with early revascularization and guide selection of patients for this strategy.
2453. Divergent nitric oxide bioavailability in men and women with sickle cell disease.
作者: Mark T Gladwin.;Alan N Schechter.;Frederick P Ognibene.;Wynona A Coles.;Christopher D Reiter.;William H Schenke.;Gyorgy Csako.;Myron A Waclawiw.;Julio A Panza.;Richard O Cannon.
来源: Circulation. 2003年107卷2期271-8页
Although reduced endothelial nitric oxide (NO) bioavailability has been demonstrated in arteriosclerotic vascular disease, the integrity of this system in sickle cell disease remains uncertain.
2454. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
作者: Shaun G Goodman.;David Fitchett.;Paul W Armstrong.;Mary Tan.;Anatoly Langer.; .
来源: Circulation. 2003年107卷2期238-44页
Current pharmacotherapeutic options for high-risk non-ST-segment elevation acute coronary syndrome patients include aspirin, clopidogrel, heparin, and platelet glycoprotein IIb/IIIa inhibition. A key issue of uncertainty is the safety and efficacy of combination glycoprotein IIb/IIIa inhibitor and low-molecular-weight heparin therapy.
2455. Simvastatin initiated early after heart transplantation: 8-year prospective experience.
作者: Klaus Wenke.;Bruno Meiser.;Joachim Thiery.;Dorothea Nagel.;Wolfgang von Scheidt.;Karl Krobot.;Gerhard Steinbeck.;Dietrich Seidel.;Bruno Reichart.
来源: Circulation. 2003年107卷1期93-7页
Randomized clinical trials have demonstrated that the use of statins in heart transplant patients lowers cholesterol levels and significantly reduces mortality and the development of transplant vasculopathy. The aim of the present study was to test these effects and the safety of statin therapy over an 8-year period.
2456. Sustained hemodynamic effects of intravenous levosimendan.
The short-term infusion of levosimendan (Levo) improves hemodynamic function in patients with decompensated heart failure. The metabolites of Levo have a prolonged half-life, and one is hemodynamically active. The goal of this study was to determine whether the hemodynamic effects of Levo are sustained during a long-term infusion and beyond the discontinuation of drug infusion.
2457. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea.
作者: Heinrich F Becker.;Andreas Jerrentrup.;Thomas Ploch.;Ludger Grote.;Thomas Penzel.;Colin E Sullivan.;J Hermann Peter.
来源: Circulation. 2003年107卷1期68-73页
There is increasing evidence that obstructive sleep apnea (OSA) is an independent risk factor for arterial hypertension. Because there are no controlled studies showing a substantial effect of nasal continuous positive airway pressure (nCPAP) therapy on hypertension in OSA, the impact of treatment on cardiovascular sequelae has been questioned altogether. Therefore, we studied the effect of nCPAP on arterial hypertension in patients with OSA.
2458. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP Study).
作者: Pranobe V Oemrawsingh.;Gary S Mintz.;Martin J Schalij.;Aeilko H Zwinderman.;J Wouter Jukema.;Ernst E van der Wall.; .
来源: Circulation. 2003年107卷1期62-7页
Long coronary lesions treated with stents have a poor outcome. This study compared the 6-month outcome of stent implantation for long lesions in patients randomized to intravascular ultrasound (IVUS; n=73) or angiographic guidance (n=71).
2459. Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina.
作者: Francesco Cipollone.;Antonina Ganci.;Anita Greco.;Maria Rosaria Panara.;Massimo Pasquale.;Domenico Di Gregorio.;Ettore Porreca.;Andrea Mezzetti.;Franco Cuccurullo.;Paola Patrignani.
来源: Circulation. 2003年107卷1期55-61页
The evidence that inflammation plays a pivotal role in the pathophysiology of acute coronary syndromes prompted us to investigate the effects of glucocorticoid treatment on leukotriene (LT) C4 and thromboxane (TX) A2 biosynthesis in unstable angina.
2460. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.
作者: Eberhard Grube.;Sigmund Silber.;Karl Eugen Hauptmann.;Ralf Mueller.;Lutz Buellesfeld.;Ulrich Gerckens.;Mary E Russell.
来源: Circulation. 2003年107卷1期38-42页
The TAXUS NIRx stent (Boston Scientific Corp) provides local delivery of paclitaxel via a slow-release polymer coating. The TAXUS I trial was the first in-human experience evaluating safety and feasibility of the TAXUS NIRx stent system compared with bare NIR stents (control) (Boston Scientific Corp) for treatment of coronary lesions.
|